Cargando…
Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma
BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317466/ https://www.ncbi.nlm.nih.gov/pubmed/30643433 http://dx.doi.org/10.2147/OTT.S189425 |
_version_ | 1783384748883705856 |
---|---|
author | Wang, Yu Yu, Weixin He, Mingqing Huang, Yan Wang, Mingyue Zhu, Jinzhou |
author_facet | Wang, Yu Yu, Weixin He, Mingqing Huang, Yan Wang, Mingyue Zhu, Jinzhou |
author_sort | Wang, Yu |
collection | PubMed |
description | BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. METHODS: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. RESULTS: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all P<0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, P=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, P<0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (P=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). CONCLUSION: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy. |
format | Online Article Text |
id | pubmed-6317466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63174662019-01-14 Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma Wang, Yu Yu, Weixin He, Mingqing Huang, Yan Wang, Mingyue Zhu, Jinzhou Onco Targets Ther Original Research BACKGROUND: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC. METHODS: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy. RESULTS: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all P<0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, P=0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, P<0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (P=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]). CONCLUSION: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy. Dove Medical Press 2018-12-31 /pmc/articles/PMC6317466/ /pubmed/30643433 http://dx.doi.org/10.2147/OTT.S189425 Text en © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Yu Yu, Weixin He, Mingqing Huang, Yan Wang, Mingyue Zhu, Jinzhou Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title | Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title_full | Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title_fullStr | Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title_full_unstemmed | Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title_short | Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
title_sort | serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317466/ https://www.ncbi.nlm.nih.gov/pubmed/30643433 http://dx.doi.org/10.2147/OTT.S189425 |
work_keys_str_mv | AT wangyu serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma AT yuweixin serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma AT hemingqing serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma AT huangyan serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma AT wangmingyue serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma AT zhujinzhou serumcytoskeletonassociatedprotein4asabiomarkerforthediagnosisofhepatocellularcarcinoma |